Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2
Yisheng Sun, Jing-Jing Zhou, Han-Ping Zhu, et al.
Viruses (2021) Vol. 13, Iss. 10, pp. 1936-1936
Open Access | Times Cited: 17

Showing 17 citing articles:

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
James Logue, Robert M. Johnson, Nita Patel, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O)
Pia Gattinger, Liubov I. Kozlovskaya, Alexander S. Lunin, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Development of an RBD-Fc fusion vaccine for COVID-19
Yisheng Sun, Qiaomin Li, Yuanyuan Luo, et al.
Vaccine X (2024) Vol. 16, pp. 100444-100444
Open Access | Times Cited: 4
Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine
Navid Dashti, Forough Golsaz‐Shirazi, Haleh Soltanghoraee, et al.
European Journal of Microbiology and Immunology (2024) Vol. 14, Iss. 3, pp. 228-242
Open Access | Times Cited: 2
Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants
Mafalda Cacciottolo, Yujia Li, Justin B Nice, et al.
PLoS ONE (2023) Vol. 18, Iss. 8, pp. e0290046-e0290046
Open Access | Times Cited: 7
A Polysaccharide-RBD-Fc-Conjugated COVID-19 Vaccine, SCTV01A, Showed High Immunogenicity and Low Toxicity in Animal Models
Chunyun Sun, Desheng Kong, Erhong Guo, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 526-526
Open Access | Times Cited: 5
Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice
Jian‐Piao Cai, Cuiting Luo, Kun Wang, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 687-687
Open Access | Times Cited: 5
Nanograms of SARS-CoV-2 Spike Protein Delivered by Exosomes Induce Potent Neutralization of Both Delta and Omicron Variants
Mafalda Cacciottolo, Yujia Li, Justin B Nice, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
Development of Nanoparticle Vaccines Utilizing Designed Fc-Binding Homo-oligomers and RBD-Fc of SARS-CoV-2
Yucai Liang, Weiling Xiao, Peng Yuan, et al.
Antiviral Research (2024) Vol. 227, pp. 105917-105917
Closed Access | Times Cited: 1
Two formulations of coronavirus disease‐19 recombinant subunit vaccine candidate made up of S1 fragment protein P1, S2 fragment protein P2, and nucleocapsid protein elicit strong immunogenicity in mice
Erkan Özcengīz, Duygu Keser, Gülay Özcengiz, et al.
Immunity Inflammation and Disease (2022) Vol. 10, Iss. 12
Open Access | Times Cited: 7
Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine
Chia‐Jung Li, Chung‐Lin Jiang, Tai‐Ling Chao, et al.
Applied Microbiology and Biotechnology (2023) Vol. 107, Iss. 9, pp. 2983-2995
Open Access | Times Cited: 3
Pre-Clinical Safety and Immunogenicity Study of a Coronavirus Protein-Based Subunit Vaccine for COVID-19
Kamshat Shorayeva, Aziz Nakhanov, Ainur Nurpeisova, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1771-1771
Open Access | Times Cited: 2
Broad‐spectrum coronavirus neutralization induced by hetero RBD‐Fc protein vaccine
Chaoyue Zhao, Guonan Cai, Shuai Jiang, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 9
Open Access
Development of a two-component recombinant vaccine for COVID-19
Yisheng Sun, Fang Xu, Han-Ping Zhu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Biochemical aspects of bioreactor operation for vaccine production
Laxmi Kumari Gupta, Harshitha Madhusoodan Jathanna, Ashish A. Prabhu
Elsevier eBooks (2024), pp. 47-64
Closed Access
Development of a scalable single process for producing SARS-CoV-2 RBD monomer and dimer vaccine antigens
Tammy Boggiano-Ayo, Julio Palacios-Oliva, Sumlai Lozada-Chang, et al.
Frontiers in Bioengineering and Biotechnology (2023) Vol. 11
Open Access | Times Cited: 1
Evaluation of the efficacy of different adjuvants in producing murine monoclonal antibodies to the receptor-binding domain of the S-protein of SARS-CoV-2
T. A. Ivashchenko, Yana O. Romanenko, M. A. Marin, et al.
Immunologiya (2023) Vol. 44, Iss. 4, pp. 481-490
Open Access
Page 1

Scroll to top